Biomek iSeries

Biomek Automated TruSight Tumor 170 Assay - Illumina Qualified

Illumina’s TruSight Tumor 170 is an enrichment-based, targeted panel NGS assay, optimized to detect 170 gene variants from common solid tumors. It simultaneously analyzes DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) cancer tissue samples or from cell lines. The method is automated on the Biomek NX P Span-8 Liquid Handler and has been Illumina Qualified. The Biomek automated TruSight Tumor 170 workflow (Fig. 1) aligns with the kit’s protocol and guarantees at least 16 RNA libraries and 16 DNA libraries can be prepared from a single reagent kit. It reduces hands-on time (Tables 1 and 2) while simplifying library prep workflow. The method interface makes setup easy: use the Method Options Selector (Fig. 2) to choose run options (e.g., number of samples), and Guided Labware Setup (Fig. 3) with automatic reagent calculation for accurate system prep that virtually eliminates setup errors.

Biomek NX P Span-8 Automated TruSight Tumor 170 • Simultaneously process up to 32 samples (16 RNA and 16 DNA) • Flexibility to select modules to run and number of samples to process (3 – 32) • Modular process preserves reagents and automates most laborious steps • Proven to deliver quality sequencing libraries revealing known variants 1